Mimetas and Astellas expand partnership to include automation and application support

The relationship between the two companies began in 2016, by accepting three scientists from Astellas for hands-on training at Mimetas.

In March 2023, a strategic partnership was announced to devise novel immuno-oncology therapies based on Mimetas comprehensive tumor models.

This partnership is to be leveraged by automation and application support, thus expanding the adoption of the Mimetas platform at Astellas.

Paul Vulto, CEO of Mimetas, said: “We are truly honored by the trust of the Astellas team in our capabilities.”

“Astellas is a true innovation leader that understands the importance of human-relevant tissue and disease modeling for novel therapy development.

“We will continue supporting Astellas with our expertise and technology to accelerate therapy development for today’s unmet medical need and contribute to Astellas’ vision to turn innovative science into patient benefits.”

Mimetas’ proprietary OrganoPlate platform enables the development and high-throughput screening of physiologically relevant disease models for drug discovery and development. The company offers its technology and expertise in therapy co-development projects, services, and off-the-shelf products.